<DOC>
	<DOC>NCT00881530</DOC>
	<brief_summary>The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criteria: patients completing one of double blind phase II trials 1245.9 or 1245.10 informed consent Exclusion criteria: patients meeting withdrawal criteria of preceding trial significant hepatic impairment significant renal impairment with creatinine clearance &lt; 50 ml/min contraindication to Metformin for all patients treated with Metformin premenopausal women that are nursing or pregnant or not practicing acceptable methods of birth control drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>